Calcifediol in the Treatment of SARS-CoV-2 Disease (COVID-19).
NCT ID: NCT06279910
Last Updated: 2025-06-05
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
230 participants
Study Classification
OBSERVATIONAL
Study Start Date
2024-02-21
Study Completion Date
2024-04-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Descriptive, retrospective, observational, anonymous, study to evaluate the potential effect of incorporating calcifediol into the therapeutic protocol of patients hospitalized for COVID-19 on mortality and other outcome variables, such as admission to the Intensive Care Unit (ICU), to "Complejo Hospitalario Universitario de Albacete" (CHUA). Albacete (Spain)", based on the files of the MXXI medical records, Information System of the Laboratory (ISL) and Pharmacy.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Calcifediol in the Treatment of COVID 19
NCT05819918
COVID-19
COMPLETED
Clinical Trial to Assess Efficacy of cYclosporine Plus Standard of Care in Hospitalized Patients With COVID19
NCT04392531
COVID19 Infection
COMPLETED
PHASE4
Diode Laser and Photodynamic Therapy Vs. Ciclopirox.
NCT05809297
Onychomycosis
UNKNOWN
PHASE4
The Effects of Repeated Exposure to Antiseptics During COVID-19 Pandemic on Skin Parameters
NCT05276102
Irritation/Irritant
ICD - Irritant Contact Dermatitis
Antiseptic
UNKNOWN
NA
Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)
NCT04335071
SARS-CoV-2 Infection
TERMINATED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The coronavirus disease-19 (COVID-19) pandemic, caused by the severe acute respiratory syndrome β-coronavirus (SARS-CoV-2), is one of the greatest challenges facing modern medicine and public health systems worldwide. Since its appearance in December 2019, it has caused nearly 7 million deaths, recognized, and confirmed worldwide, with high acute and post-acute morbidity, making it one of the deadliest in human history, with a devastating impact on national economies worldwide.
In the first outbreaks of COVID-19, although 80% were asymptomatic or had mild symptoms, 20% of patients developed severe symptoms, and 5% presented acute respiratory distress syndrome (ARDS), septic shock and accompanied multi-organ organ failure, with a high risk of death. Numerous risk factors have been described that influence the poor outcome of these patients, such as age, sex, high blood pressure, chronic obstructive pulmonary disease, diabetes, obesity, chronic lung and digestive diseases, asthma, chronic heart disease, cancer, D-dimer greater than 1000, or a high SOFA (Sequential Organ Failure Assessment Score). It has also been observed that patients with no a priori risk factors may have a poor outcome.
The scientific community immediately proposed strong social containment measures, quickly developed effective vaccines to prevent the appearance of severe clinical forms of COVID-19, and developed new treatments against all aspects of the disease: antiviral agents, anti-inflammatory agents, antithrombotic therapies, therapies against hypoxemic acute respiratory failure, therapies with anti-SARS-CoV-2 antibodies (neutralizing), modulators of the renin-angiotensin-aldosterone system and vitamins, so that social and economic activity has gradually recovered worldwide.
However, at the current time, there are some indications that hospital admissions for COVID-19 are on the rise again, so the pandemic seems far from over and future waves of infection are likely. These indications update and highlight again the repositioning strategy used since the beginning of the pandemic for the use of safe drugs, approved for another indication, and redirected to improve symptoms and clinical outcomes in patients with COVID-19. Various drugs have been investigated under this strategy and many studies have been published, some of them successful.
In this sense, during the first months of the pandemic, on the basis of biological plausibility, the investigators thought that the activation of the vitamin D receptor (VDR) signaling pathway of the vitamin D endocrine system (VDES) could produce beneficial effects in COVID-19. These effects were achieved by improving innate antiviral effector mechanisms, facilitating the induction of antimicrobial peptides/autophagy, mitigating the subsequent reactive hyperinflammatory phase of the host, decreasing the cytokine/chemokine storm, modulating the expression of the renin angiotensin system (RAAS) and neutrophil activity, maintaining the integrity of the pulmonary/intestinal epithelial barrier, stimulating epithelial repair and directly and indirectly reducing the increase in coagulability and prothrombotic tendency associated with a severe course of COVID-19 and its complications. Available evidence suggests that VDES/VDR stimulation, while maintaining optimal serum 25-hydroxyvitamin D \[(25(OH)D)\] status, in patients with SARS-CoV-2 infection may significantly reduce the risk of distress syndrome, acute respiratory distress syndrome (ARDS) and the development of severe COVID-19.
The investigators decided to use calcifediol, which is a prohormone (and cornerstone of the VDES) and substrate for the synthesis of the system's hormone, calcitriol. The poor availability of calcifediol described in the general population, most marked in patients affected by COVID, means that the potential protection that VDR/VDES stimulation confers against various aspects of the disease is lost.
Calcifediol provides pharmacokinetic advantages, which give it a certain functional superiority over native vitamin D3 and even over the hormonal form of VDES, calcitriol, for its use in COVID-19. It is very hydrophilic and, therefore, after oral ingestion, it is absorbed through the portal venous system and does not require hydroxylation at the 25 position, immediately increasing optimal circulating concentrations of 25(OH)D3. Therefore, even if administered orally, it is available at high concentrations within a few hours, and in a stable manner, to be a substrate for calcitriol synthesis at the kidney and other target organs in COVID-19.
The clinical trial pilot study and several observational intervention studies using relatively high doses of calcifediol (0.532 µg on day 1 and 0.266 µg on days 3, 7, 14, 21 and 28) decreased the severity of the disease, dramatically reducing the need for ICU admission, severity, and mortality rate.
Therefore, using calcifediol at the doses described for rapid correction of 25(OH)D deficiency in all patients in the early stages of COVID-19, in association with the best available therapy, was assessed as a good option for the treatment of COVID-19. For this reason, on January 24, 2021, the CHUA incorporated calcifediol into the protocol "Recommendations for action and treatment of the coronavirus SARS-CoV-2 disease" (COVID-19) version 11.1".
In the first outbreaks of COVID-19, although 80% were asymptomatic or had mild symptoms, 20% of patients developed severe symptoms, and 5% presented acute respiratory distress syndrome (ARDS), septic shock and accompanied multi-organ organ failure, with a high risk of death. Numerous risk factors have been described that influence the poor outcome of these patients, such as age, sex, high blood pressure, chronic obstructive pulmonary disease, diabetes, obesity, chronic lung and digestive diseases, asthma, chronic heart disease, cancer, D-dimer greater than 1000, or a high SOFA (Sequential Organ Failure Assessment Score). It has also been observed that patients with no a priori risk factors may have a poor outcome.
The scientific community immediately proposed strong social containment measures, quickly developed effective vaccines to prevent the appearance of severe clinical forms of COVID-19, and developed new treatments against all aspects of the disease: antiviral agents, anti-inflammatory agents, antithrombotic therapies, therapies against hypoxemic acute respiratory failure, therapies with anti-SARS-CoV-2 antibodies (neutralizing), modulators of the renin-angiotensin-aldosterone system and vitamins, so that social and economic activity has gradually recovered worldwide.
However, at the current time, there are some indications that hospital admissions for COVID-19 are on the rise again, so the pandemic seems far from over and future waves of infection are likely. These indications update and highlight again the repositioning strategy used since the beginning of the pandemic for the use of safe drugs, approved for another indication, and redirected to improve symptoms and clinical outcomes in patients with COVID-19. Various drugs have been investigated under this strategy and many studies have been published, some of them successful.
In this sense, during the first months of the pandemic, on the basis of biological plausibility, the investigators thought that the activation of the vitamin D receptor (VDR) signaling pathway of the vitamin D endocrine system (VDES) could produce beneficial effects in COVID-19. These effects were achieved by improving innate antiviral effector mechanisms, facilitating the induction of antimicrobial peptides/autophagy, mitigating the subsequent reactive hyperinflammatory phase of the host, decreasing the cytokine/chemokine storm, modulating the expression of the renin angiotensin system (RAAS) and neutrophil activity, maintaining the integrity of the pulmonary/intestinal epithelial barrier, stimulating epithelial repair and directly and indirectly reducing the increase in coagulability and prothrombotic tendency associated with a severe course of COVID-19 and its complications. Available evidence suggests that VDES/VDR stimulation, while maintaining optimal serum 25-hydroxyvitamin D \[(25(OH)D)\] status, in patients with SARS-CoV-2 infection may significantly reduce the risk of distress syndrome, acute respiratory distress syndrome (ARDS) and the development of severe COVID-19.
The investigators decided to use calcifediol, which is a prohormone (and cornerstone of the VDES) and substrate for the synthesis of the system's hormone, calcitriol. The poor availability of calcifediol described in the general population, most marked in patients affected by COVID, means that the potential protection that VDR/VDES stimulation confers against various aspects of the disease is lost.
Calcifediol provides pharmacokinetic advantages, which give it a certain functional superiority over native vitamin D3 and even over the hormonal form of VDES, calcitriol, for its use in COVID-19. It is very hydrophilic and, therefore, after oral ingestion, it is absorbed through the portal venous system and does not require hydroxylation at the 25 position, immediately increasing optimal circulating concentrations of 25(OH)D3. Therefore, even if administered orally, it is available at high concentrations within a few hours, and in a stable manner, to be a substrate for calcitriol synthesis at the kidney and other target organs in COVID-19.
The clinical trial pilot study and several observational intervention studies using relatively high doses of calcifediol (0.532 µg on day 1 and 0.266 µg on days 3, 7, 14, 21 and 28) decreased the severity of the disease, dramatically reducing the need for ICU admission, severity, and mortality rate.
Therefore, using calcifediol at the doses described for rapid correction of 25(OH)D deficiency in all patients in the early stages of COVID-19, in association with the best available therapy, was assessed as a good option for the treatment of COVID-19. For this reason, on January 24, 2021, the CHUA incorporated calcifediol into the protocol "Recommendations for action and treatment of the coronavirus SARS-CoV-2 disease" (COVID-19) version 11.1".
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
SARS-CoV 2 Pneumonia
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
CASE_CONTROL
Study Time Perspective
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients treated with calcifediol
Patients admitted to the CHUA, due to COVID-19 \[respiratory infection confirmed by radiographic pattern of viral pneumonia and positive polymerase chain reaction (PCR)/antigen for SARS-CoV-2\] treated with calcifediol
Calcifediol
Intervention Type
DRUG
Calcifediol added as a treatment to the rest of the prescribed drugs of the protocol
Patients not treated with calcifediol
Patients admitted to the CHUA, due to COVID-19 (respiratory infection confirmed by radiographic pattern of viral pneumonia and positive PCR/antigen for SARS-CoV-2) not treated with calcifediol
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Calcifediol
Calcifediol added as a treatment to the rest of the prescribed drugs of the protocol
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Admitted to the hospital CHUA
2. Meet the SARS-CoV-2 diagnostic criteria with positive PCR
3. They have completed at least the first dose of Calcifediol within the first 72 hours after admission, (according to protocol).
2. Meet the SARS-CoV-2 diagnostic criteria with positive PCR
3. They have completed at least the first dose of Calcifediol within the first 72 hours after admission, (according to protocol).
Exclusion Criteria
1. Patients who do not receive the full first dose of Calcifediol within the first 72 hours.
2. Patients for whom electronic medical record data cannot be collected.
3. Patients with other serious intercurrent diseases (eg advanced oncological pathology).
2. Patients for whom electronic medical record data cannot be collected.
3. Patients with other serious intercurrent diseases (eg advanced oncological pathology).
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Complejo Hospitalario Universitario de Albacete
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Javier Torres, PhD
Role: STUDY_CHAIR
Complejo Hospitalario Universitario de Albacete. Albacete. Spain
Jose M Quesada, MD
Role: STUDY_DIRECTOR
Maimónides Biomedical Research Institute of Córdoba (IMIBIC). Córdoba. Spain
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Complejo Hospitalario Universitario de Albacete
Albacete, Albacete, Spain
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Spain
References
Explore related publications, articles, or registry entries linked to this study.
Ranabhat CL, Jakovljevic M, Kim CB, Simkhada P. COVID-19 Pandemic: An Opportunity for Universal Health Coverage. Front Public Health. 2021 Jul 29;9:673542. doi: 10.3389/fpubh.2021.673542. eCollection 2021. No abstract available.
Reference Type
BACKGROUND
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W; China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727-733. doi: 10.1056/NEJMoa2001017. Epub 2020 Jan 24.
Reference Type
BACKGROUND
Bowe B, Xie Y, Al-Aly Z. Postacute sequelae of COVID-19 at 2 years. Nat Med. 2023 Sep;29(9):2347-2357. doi: 10.1038/s41591-023-02521-2. Epub 2023 Aug 21.
Reference Type
BACKGROUND
Giliberto Capano, Michael Howlett, Darryl S L Jarvis, M Ramesh, Long-term policy impacts of the coronavirus: normalization, adaptation, and acceleration in the post-COVID state, Policy and Society, 2022; 41 (1): 1-12, doi: 10.1093/polsoc/puab018
Reference Type
BACKGROUND
Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020 Aug 25;324(8):782-793. doi: 10.1001/jama.2020.12839.
Reference Type
BACKGROUND
Pritchard E, Matthews PC, Stoesser N, Eyre DW, Gethings O, Vihta KD, Jones J, House T, VanSteenHouse H, Bell I, Bell JI, Newton JN, Farrar J, Diamond I, Rourke E, Studley R, Crook D, Peto TEA, Walker AS, Pouwels KB. Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. Nat Med. 2021 Aug;27(8):1370-1378. doi: 10.1038/s41591-021-01410-w. Epub 2021 Jun 9.
Reference Type
BACKGROUND
Murakami N, Hayden R, Hills T, Al-Samkari H, Casey J, Del Sorbo L, Lawler PR, Sise ME, Leaf DE. Therapeutic advances in COVID-19. Nat Rev Nephrol. 2023 Jan;19(1):38-52. doi: 10.1038/s41581-022-00642-4. Epub 2022 Oct 17.
Reference Type
BACKGROUND
El-Sadr WM, Vasan A, El-Mohandes A. Facing the New Covid-19 Reality. N Engl J Med. 2023 Feb 2;388(5):385-387. doi: 10.1056/NEJMp2213920. Epub 2023 Jan 28. No abstract available.
Reference Type
BACKGROUND
The Lancet. The COVID-19 pandemic in 2023: far from over. Lancet. 2023 Jan 14;401(10371):79. doi: 10.1016/S0140-6736(23)00050-8. No abstract available.
Reference Type
BACKGROUND
Kato Y, Nishiyama K, Nishimura A, Noda T, Okabe K, Kusakabe T, Kanda Y, Nishida M. Drug repurposing for the treatment of COVID-19. J Pharmacol Sci. 2022 Jul;149(3):108-114. doi: 10.1016/j.jphs.2022.04.007. Epub 2022 Apr 25.
Reference Type
BACKGROUND
Quesada-Gomez JM, Entrenas-Castillo M, Bouillon R. Vitamin D receptor stimulation to reduce acute respiratory distress syndrome (ARDS) in patients with coronavirus SARS-CoV-2 infections: Revised Ms SBMB 2020_166. J Steroid Biochem Mol Biol. 2020 Sep;202:105719. doi: 10.1016/j.jsbmb.2020.105719. Epub 2020 Jun 11.
Reference Type
BACKGROUND
Quesada-Gomez JM, Lopez-Miranda J, Entrenas-Castillo M, Casado-Diaz A, Nogues Y Solans X, Mansur JL, Bouillon R. Vitamin D Endocrine System and COVID-19: Treatment with Calcifediol. Nutrients. 2022 Jun 29;14(13):2716. doi: 10.3390/nu14132716.
Reference Type
BACKGROUND
Quesada-Gomez JM, Bouillon R. Calcifediol Cornerstone of the Vitamin D Endocrine System. Nutrients. 2023 May 12;15(10):2290. doi: 10.3390/nu15102290.
Reference Type
BACKGROUND
Lips P, Cashman KD, Lamberg-Allardt C, Bischoff-Ferrari HA, Obermayer-Pietsch B, Bianchi ML, Stepan J, El-Hajj Fuleihan G, Bouillon R. Current vitamin D status in European and Middle East countries and strategies to prevent vitamin D deficiency: a position statement of the European Calcified Tissue Society. Eur J Endocrinol. 2019 Apr;180(4):P23-P54. doi: 10.1530/EJE-18-0736.
Reference Type
BACKGROUND
Wang Z, Joshi A, Leopold K, Jackson S, Christensen S, Nayfeh T, Mohammed K, Creo A, Tebben P, Kumar S. Association of vitamin D deficiency with COVID-19 infection severity: Systematic review and meta-analysis. Clin Endocrinol (Oxf). 2022 Mar;96(3):281-287. doi: 10.1111/cen.14540. Epub 2021 Jul 12.
Reference Type
BACKGROUND
Bouillon R, Quesada-Gomez JM. Vitamin D Endocrine System and COVID-19. JBMR Plus. 2021 Nov 17;5(12):e10576. doi: 10.1002/jbm4.10576. eCollection 2021 Dec.
Reference Type
BACKGROUND
Bouillon R, Quesada Gomez JM. Comparison of calcifediol with vitamin D for prevention or cure of vitamin D deficiency. J Steroid Biochem Mol Biol. 2023 Apr;228:106248. doi: 10.1016/j.jsbmb.2023.106248. Epub 2023 Jan 13.
Reference Type
BACKGROUND
Entrenas Castillo M, Entrenas Costa LM, Vaquero Barrios JM, Alcala Diaz JF, Lopez Miranda J, Bouillon R, Quesada Gomez JM. "Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study". J Steroid Biochem Mol Biol. 2020 Oct;203:105751. doi: 10.1016/j.jsbmb.2020.105751. Epub 2020 Aug 29.
Reference Type
BACKGROUND
Nogues X, Ovejero D, Pineda-Moncusi M, Bouillon R, Arenas D, Pascual J, Ribes A, Guerri-Fernandez R, Villar-Garcia J, Rial A, Gimenez-Argente C, Cos ML, Rodriguez-Morera J, Campodarve I, Quesada-Gomez JM, Garcia-Giralt N. Calcifediol Treatment and COVID-19-Related Outcomes. J Clin Endocrinol Metab. 2021 Sep 27;106(10):e4017-e4027. doi: 10.1210/clinem/dgab405.
Reference Type
BACKGROUND
Alcala-Diaz JF, Limia-Perez L, Gomez-Huelgas R, Martin-Escalante MD, Cortes-Rodriguez B, Zambrana-Garcia JL, Entrenas-Castillo M, Perez-Caballero AI, Lopez-Carmona MD, Garcia-Alegria J, Lozano Rodriguez-Mancheno A, Arenas-de Larriva MDS, Perez-Belmonte LM, Jungreis I, Bouillon R, Quesada-Gomez JM, Lopez-Miranda J. Calcifediol Treatment and Hospital Mortality Due to COVID-19: A Cohort Study. Nutrients. 2021 May 21;13(6):1760. doi: 10.3390/nu13061760.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021 36 (EOm)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19
NCT04622865
UNKNOWN
PHASE2
Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Moderate COVID19.
NCT05770466
COMPLETED
PHASE3
Camostat and Artemisia Annua vs Placebo in COVID-19 Outpatients
NCT04530617
TERMINATED
PHASE2
Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail
NCT01270971
COMPLETED
PHASE3
Bioavailability of BI 144807 Given Alone and in Combination With Ketoconazole in Healthy Male Volunteers
NCT01707940
COMPLETED
PHASE1
IMUNOR® Preparation in the Prevention of COVID-19
NCT04710381
COMPLETED
PHASE4
Study to Determine the Effect of Ketoconazole on the Pharmacokinetics of GDC-0980
NCT01473316
COMPLETED
PHASE1
Relative Bioavailability of of Olodaterol and Ketoconazole
NCT01153711
COMPLETED
PHASE1
A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Linifanib (ABT-869)
NCT01114191
COMPLETED
PHASE1
Drug Interaction Study to Investigate Co-administration of GW642444M With Ketoconazole
NCT00866515
COMPLETED
PHASE1
Use of Essential Oils as Natural Therapies
NCT05777525
COMPLETED
PHASE3
Chlorhexidine Scrub, ZnO Nanoparticles Socks and the Combination for Prevention of Pitted Keratolysis
NCT04337749
WITHDRAWN
PHASE4
Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail
NCT00443820
COMPLETED
PHASE3
TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With COVID-19 Interstitial Pneumonia
NCT04390061
UNKNOWN
PHASE2
Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail
NCT01302119
COMPLETED
PHASE3
A Study of the Effects of Increasing Doses of a Drug for the Treatment of Nail Fungus
NCT01014962
COMPLETED
PHASE1
Ivermectin Reproposing for Mild Stage COVID-19 Outpatients
NCT04784481
COMPLETED
PHASE1/PHASE2
Comparative Safety and Efficacy Study of New Bifonazol Spray vs Terbinafine Solution vs Placebo
NCT01013909
COMPLETED
PHASE2
Effectiveness of Podiatry Care on Onychomycosis (EPOCAON)
NCT00938925
WITHDRAWN
NA
Efficacy Study to Evaluate the Effect of Nitric Oxide on the Treatment of Tinea Pedis (Athlete's Foot)
NCT00771342
COMPLETED
PHASE2
Omiganan Twice a Day (BID) in Patients With Facial Seborrheic Dermatitis
NCT03688971
UNKNOWN
PHASE2
Safety and Efficacy Study of Subjects With Onychomycosis of the Great Toenail
NCT01278394
COMPLETED
PHASE2
Clinical Trial Comparing Dapaconazole Versus Miconazole in Patients With Tinea Cruris
NCT03359070
COMPLETED
PHASE2